In 536 patients with advanced gastric cancer after fluoropyrimidine-based therapy, paclitaxel oral solution improved overall survival vs paclitaxel injection (9.13 vs 6.54 months; HR 0.770) and was non-inferior for PFS (3.02 vs 2.89 months), with less neuropathy.
RCTn = 536
Li et al. Paclitaxel oral solution versus paclitaxel injection as second-line therapy for advanced gastric cancer: a multicenter, open-label, randomized phase III trial